Biopharmaceutical company Gilead Sciences has completed the acquisition of YM BioSciences. A Gilead subsidiary acquired all YM's outstanding common shares as per the terms of a plan of arrangement. Thus, YM has become a wholly-owned ...
Tags: Gilead Sciences, YM BioSciences, acquisition
Gilead Sciences, a biopharmaceutical company, has submitted a new drug application (NDA) to the FDA for HIV integrase inhibitor elvitegravir for the treatment-experienced patients. The company provided 96-week data from a pivotal Phase ...
Aptalis Pharmaceutical Technologies announced that the European Commission has approved the marketing authorization of new oral granule formulation of Gilead Sciences' Viread, covering 27 countries of the European Union. Viread is ...
Tags: oral granule formulation, Pharmaceutical Technologies, Pharmaceutical
The Antiviral Drugs Advisory Committee of the FDA has recommended the approval of Gilead's Quad to treat HIV-1 infection in treatment-naive adults. The Quad is a complete single tablet regimen of elvitegravir, cobicistat, emtricitabine ...
Tags: gilead's quad, HIV-1, quad NDA
Gilead Sciences Truvada (emtricitabine and tenofovir disoproxil fumarate) has received approval from the US Food and Drug Administration (FDA). Truvada is the first agent to get approval for HIV prevention in uninfected adults, a strategy ...
Tags: HIV testing, Truvada, PrEP, pre-exposure prophylaxis
Gilead Sciences has received US Food and Drug Administration (FDA) approval for Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg). Stribild is a complete once-daily single tablet ...